Results 111 to 120 of about 340,819 (312)
Background: Value-based sarcoma care requires outcome measures that reflect the patient perspective; however, many sarcoma episodes begin with near-normal function and undergo necessary morbidity for oncologic control, making simple “improvement” an ...
Isabel Gloor +8 more
doaj +1 more source
A rare de novo IFT122‐A773E variant is identified in idiopathic pediatric uveitis and shown to exacerbate retinal inflammation and barrier dysfunction. Mechanistically, the variant enhances IFT43 interaction, elevates calcium signaling, and activates the MEK/ERK/FRA1 axis, revealing a previously unrecognized cilia‐associated pathway that may increase ...
Qian Zhou +18 more
wiley +1 more source
EBV‑BZLF1 initiates ODC1‑driven polyamine anabolism that correlates with poor clinical prognosis in nasopharyngeal carcinoma. The ODC1–spermidine axis promotes viral replication, cell proliferation and innate immune evasion. Pharmacological inhibition of ODC1 rescues cisplatin sensitivity, establishing ODC1 as a viable therapeutic target for EBV ...
Yueshuo Li +9 more
wiley +1 more source
Sarcoma histiocitico mediastinico en un perro Bernés de la Montaña [PDF]
15 páginasHistiocytes are a subclassification of leukocytes, whose main function is essentially directed to the immune system, these cells are derived from the bone marrow from CD34 + precursor cells that form two types of cell lines monocytes ...
Herrera Alfonso, Brayan David
core +1 more source
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang +5 more
wiley +1 more source
Summary: Rare cancers account for approximately one quarter of cancer diagnoses in Europe, yet prevailing clinical trial governance frameworks were developed for common malignancies and conventional randomised designs.
Ornella Gonzato +4 more
doaj +1 more source
Uterine sarcoma – current perspectives
Charlotte Benson,1 Aisha B Miah1,2 1Sarcoma Unit, Royal Marsden Hospital, 2Department of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK Abstract: Uterine sarcomas comprise a group of rare tumors with differing tumor biology ...
Benson C, Miah AB
core
Associations of Classic Kaposi Sarcoma with Common Variants in Genes that Modulate Host Immunity
Classic Kaposi sarcoma (CKS) is an inflammatory-mediated neoplasm primarily caused by Kaposi sarcoma-associated herpesvirus (KSHV). Kaposi sarcoma lesions are characterized, in part, by the presence of proinflammatory cytokines and growth factors thought
WHITBY D +15 more
core +1 more source
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu +7 more
wiley +1 more source

